Activation of M2 muscarinic acetylcholine receptors by a hybrid agonist enhances cytotoxic effects in GB7 glioblastoma cancer stem cells

Neurochem Int. 2018 Sep:118:52-60. doi: 10.1016/j.neuint.2018.04.010. Epub 2018 Apr 24.

Abstract

In previous studies, we found that the orthosteric muscarinic agonist arecaidine propargyl ester (APE) (100 μM) induced a decreased cell proliferation and severe apoptosis in glioblastoma cancer stem cells (GSCs). In this report, we have investigated the effects mediated by hybrid (orthosteric/allosteric) muscarinic agonists P-6-Iper and N-8-Iper on GSCs survival. At variance with APE, the agonist N-8-Iper inhibited cell growth in a dose dependent manner and also impaired cell survival at low doses. The inhibitory effects of the N-8-Iper action appear to be mediated by M2 receptor activation, since they were strongly reduced by co-administration of the selective M2 receptor antagonist methoctramine as well as upon M2 receptor silencing. Moreover, analysis of the expression of phosphorylated histone H2AX (γ-H2AX) indicated that the treatment with N-8-Iper produced a decreased cell survival by induction of DNA damage. The ability of N-8-Iper to produce a cytotoxic effect and apoptosis at low doses indicates that this muscarinic agonist is a suitable probe in a putative therapeutic intervention on glioblastoma through M2 receptor activation.

Keywords: Cancer stem cells; Cell death; DNA damage; Dualsteric (allosteric/orthosteric) activators; M2 muscarinic acetylcholine receptors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Line, Tumor
  • Cell Survival / drug effects
  • Cell Survival / physiology
  • DNA Damage / drug effects
  • DNA Damage / physiology
  • Dose-Response Relationship, Drug
  • Glioblastoma / pathology*
  • Humans
  • Muscarinic Agonists / pharmacology*
  • Neoplastic Stem Cells / drug effects*
  • Neoplastic Stem Cells / pathology*
  • Receptor, Muscarinic M2 / agonists*
  • Receptor, Muscarinic M2 / metabolism

Substances

  • Muscarinic Agonists
  • Receptor, Muscarinic M2